for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aslan Pharmaceuticals Ltd

ASLN.OQ

Latest Trade

1.58USD

Change

-0.11(-6.51%)

Volume

1,662

Today's Range

1.57

 - 

1.70

52 Week Range

1.45

 - 

7.80

As of on the Gre Tai Security Market ∙ Minimum 15 minute delay

Pricing

Previous Close
1.69
Open
1.68
Volume
1,662
3M AVG Volume
5.49
Today's High
1.70
Today's Low
1.57
52 Week High
7.80
52 Week Low
1.45
Shares Out (MIL)
160.25
Market Cap (MIL)
1,570.44
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Aslan Pharmaceuticals Files For Offering Of 4.6 Mln American Depositary Shares Representing 23.1 Mln Ordinary Shares

Aslan Pharmaceuticals Files Preliminary Prospectus Related To Offering ADS

Aslan Pharmaceuticals Acquires Full Global Commercial Rights For ASLAN004 From CSL

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aslan Pharmaceuticals Ltd

ASLAN PHARMACEUTICALS LIMITED is a company engaged in the research and development of new pharmaceuticals. The Company locates its headquarters in Singapore and set up outposts in Taiwan, China and Australia to create a cross-regional platform. Through this platform, the Company is authorized to introduce pharmaceuticals from international pharmaceutical factories and biotechnology companies and it is also involved in the later production and clinical activities. The Company owns five products at the research and development stage which are mainly targeted at indications including biliary tract, gastric, breast and colorectal cancers.

Industry

Biotechnology & Drugs

Contact Info

83 Clemenceau Avenue, #12-03 Ue Square

+65.6.2224235

http://aslanpharma.com/zh/

Executive Leadership

Andrew James Howden

Chairman of the Board

Carl Firth

Chief Executive Officer, Director

Mark McHale

Chief Operating Officer

Kiran Asarpota

Vice President-Finance

Zhiyi Xie

Chief Medical Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
17.00
Price To Book (MRQ)
2.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
82.20
LT Debt To Equity (MRQ)
80.90
Return on Investment (TTM)
-71.96
Return on Equity (TTM)
-64.17

Latest News

Latest News

BRIEF-Aslan Pharmaceuticals Ltd Sees U.S. IPO Of Up To 7.5 Million American Depositary Shares - SEC Filing

* ASLAN PHARMACEUTICALS LTD SEES U.S. IPO OF UP TO 7.5 MILLION AMERICAN DEPOSITARY SHARES - SEC FILING Source text: (https://bit.ly/2vfvyuJ) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-‍Aslan Pharmaceuticals Files For Proposed IPO In U.S.​

* ASLAN PHARMACEUTICALS FILES FOR PROPOSED INITIAL PUBLIC OFFERING IN U.S.

BRIEF-Aslan Pharmaceuticals Files For U.S. IPO

* ASLAN PHARMACEUTICALS LIMITED FILES FOR U.S. IPO OF UP TO $86.3 MILLION – SEC FILING

BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib

* ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA

BRIEF-Aslan Pharmaceuticals unit to issue 67 mln new shares at T$38 per share

* Says its unit ASLAN Pharmaceuticals Pte. Ltd plans to issue 67 million new shares at T$38 per share

BRIEF-Aslan Pharmaceuticals plan private placement of up to 45 mln shares

* Says it plans to issue up to 45 million new shares via private placement, with details remaining to be determined

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up